Corcept Therapeutics Inc. (NASDAQ:CORT) is set to announce its quarterly earnings on February 24, 2026, after the market closes. Analysts predict an earnings per share (EPS) of $0.33 and revenue of around $254.9 million. CORT, a biopharmaceutical company, focuses on developing drugs to treat severe metabolic, oncologic, and psychiatric disorders.
Despite the upcoming earnings report, CORT faces challenges. A securities class action lawsuit, filed by the Allegheny County Employees' Retirement System, claims the company ignored FDA warnings about its lead product, relacorilant. This has led to a 50% drop in CORT's stock price, affecting investor confidence.
CORT's financial metrics provide insight into its market position. The company has a price-to-earnings (P/E) ratio of 36.73, indicating investor willingness to pay for each dollar of earnings. Its price-to-sales ratio is 5.29, reflecting the market's valuation of its revenue. The enterprise value to sales ratio is 5.13, slightly lower than its market capitalization relative to sales.
The company's financial health appears strong, with a low debt-to-equity ratio of 0.01, showing minimal reliance on debt. CORT's current ratio of 3.14 suggests it can cover short-term liabilities with its current assets. However, the enterprise value to operating cash flow ratio of 23.37 indicates a high valuation relative to cash flow from operations.
Investors affected by the stock's decline are encouraged to contact the law firm Hagens Berman. The deadline for lead plaintiff applications is April 21. As CORT prepares to release its earnings, the lawsuit and its financial metrics will be closely watched by investors and analysts alike.
